Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme,
Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company
developing novel epigenetic therapies, today announced that management
will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to
discuss updated data from an ongoing Phase 2 study of its lead
candidate, tazemetostat, as a monotherapy for patients with relapsed or
refractory follicular lymphoma. The data, which will be from a recent
June 2019 data cutoff date, will be reported in an oral presentation by
Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional
Universitaire and study investigator, at the International Conference on
Malignant Lymphoma (ICML) in Lugano, Switzerland.

The details of the presentation and the company’s conference call are
listed below:

ICML Oral Presentation
Title: Interim update from a Phase 2
multicenter study of tazemetostat, an EZH2 inhibitor, in patients with
relapsed or refractory follicular lymphoma
Presenter: Franck
Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire
de Lille, France
Abstract No.: 105
Date: Friday, June 21,
2019; 2:45 – 3:00 p.m. CEST
Location: Room A

Conference Call Details
To participate in the call, please
dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and
refer to conference ID 7765222. A live webcast will be available in the
investor section of the company’s website at www.epizyme.com.
The webcast will be archived on the website for 60 days.

About Epizyme, Inc.
Epizyme, Inc. is a late-stage
biopharmaceutical company committed to rewriting treatment for cancer
and other serious diseases through novel epigenetic medicines. Epizyme
is broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies, as a monotherapy and combination
therapy in relapsed and front-line disease. The company also is
developing a novel G9a program with its next development candidate,
EZM8266, which is targeting sickle cell disease. By focusing on the
genetic drivers of disease, Epizyme’s science seeks to match targeted
medicines with the patients who need them. For more information, visit www.epizyme.com.

Cautionary Note on Forward-Looking Statements
Any statements
in this press release about future expectations, plans and prospects for
Epizyme, Inc. and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: uncertainties inherent in the initiation
of future clinical studies and in the availability and timing of data
from ongoing clinical studies; whether interim results from a clinical
trial will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will be
predictive of the results of future trials; whether results from
clinical studies will warrant meetings with regulatory authorities,
submissions for regulatory approval or review by governmental
authorities under the accelerated approval process; whether Fast Track
Designation and Orphan Drug Designations will provide the benefits for
which tazemetostat is eligible; whether the NDA submission referred to
in this release will be accepted for review under the accelerated
approval process or at all, or approved on a timely basis or at all;
whether the company’s cash resources will be sufficient to fund the
company’s foreseeable and unforeseeable operating expenses and capital
expenditure requirements; other matters that could affect the
availability or commercial potential of the company’s therapeutic
candidates; and other factors discussed in the “Risk Factors” section of
the company’s most recent Form 10-Q filed with the SEC and in the
company’s other filings from time to time with the SEC. In addition, the
forward-looking statements included in this press release represent the
company’s views as of the date hereof and should not be relied upon as
representing the company’s views as of any date subsequent to the date
hereof. The company anticipates that subsequent events and developments
will cause the company’s views to change.

Contacts

Media:
Erin Graves, (617) 500-0615
Epizyme, Inc.
[email protected]

Investors:
Chelcie
Lister, (919) 777-3049
THRUST Strategic Communications
[email protected]